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Outcomes of UCB transplantation are comparable in FLT3+
AML: results of CIBMTR, EUROCORD and EBMT
collaborative analysis
C Ustun1, F Giannotti2,3, M-J Zhang4,5, H-L Wang4, C Brunstein6, M Labopin7,8, V Rocha9, M de Lima10, F Baron11, BM Sandmaier12,
M Eapen4, E Gluckman3,13, A Nagler14,15, DJ Weisdorf16 and A Ruggeri2,3
Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may
improve leukemia-free survival (LFS) in FMS-like tyrosine kinase 3+ (FLT3+) acute myeloid leukemia (AML), which has poor
prognosis because of high relapse rates. Umbilical cord blood (UCB) HCT outcomes are largely unknown in this population. We
found that compared with sibling HCT, relapse risks were similar after UCB (n= 126) (hazard ratio (HR) 0.86, P= 0.54) and URD
(n= 91) (HR 0.81, P= 0.43). UCB HCT was associated with statistically higher non-relapse mortality compared with sibling HCT (HR
2.32, P= 0.02), but not vs URD (HR 1.72, P= 0.07). All three cohorts had statistically nonsignificant 3-year LFS: 39% (95% confidence
interval (CI): 30–47) after UCB, 43% (95% CI: 30–54) after sibling and 50% (95% CI: 40–60) after URD. Chronic graft-versus-host
disease rates were significantly lower after UCB compared with either sibling (HR 0.59, P= 0.03) or URD (HR 0.49, P= 0.001). Adverse
factors for LFS included high leukocyte count at diagnosis and HCT during CR2 (second CR). UCB is a suitable option for adults with
FLT3+ AML in the absence of an human leukocyte antigen-matched sibling and its immediate availability may be particularly
important for FLT3+ AML where early relapse is common, thus allowing HCT in CR1 (first CR) when outcomes are best.
Leukemia (2017) 31, 1408–1414; doi:10.1038/leu.2017.42
INTRODUCTION
FMS-like tyrosine kinase (FLT3), a receptor tyrosine kinase (TK), is
present in early hematopoietic progenitors and influences the
survival, proliferation and differentiation of hematopoietic cells.
Mutation in the FLT3 gene (FLT3+) has been reported in acute
myeloid leukemia (AML). The internal tandem duplication (FLT3-
ITD, 15–35%) and missense point mutations (5–10%) in the TK
domain (TKD) are the most commonly detected mutations in the
FLT3 gene.1,2 These mutations confer ligand-independent con-
stitutive activation of the FLT3 kinase and its downstream
signaling pathway, which stimulates AML cell proliferation.3
Patients with FLT3+ AML share clinical, cytogenetic and molecular
common features at diagnosis, typically presenting with high
white blood cell (WBC) counts, normal cytogenetics, presence of
the nucleophosmin (NPM1) gene mutation and FAB subtypes M4
and M5.1 However, the prognosis of patients with FLT3+ AML is
poor mainly because of frequent and early relapse in both adult
and pediatric populations.4–10
Allogeneic hematopoietic cell transplantation (HCT) for FLT3+
AML from sibling or unrelated donors (URDs) has been most often
reported in first complete remission (CR1) given the poor prognosis
of disease.11–19 Leukemia-free survival (LFS) at 2 years after HCT
approximates to 50–60% in most studies,8,13,20,21 although it ranges
widely from 20% (refs 5,15) to 70%.22 Umbilical cord blood (UCB)
HCT has increasingly been used for patients when suitable human
leukocyte antigen-matched donors are unavailable and when
proceeding to transplantation is urgent,23–29 potentially as in FLT3
+ AML. The outcomes of UCB HCT are reportedly similar to sibling or
URD HCT for various diseases.24,30,31 The outcomes of patients with
FLT3+ AML after UCB HCT are largely unknown, except for a recent
University of Minnesota report.32
In this large retrospective study, we compared the efficacy of
UCB HCT with matched sibling and URD grafts in FLT3+ AML using
data from three large international observational registries. We
hypothesized that relapse and LFS after UCB HCT would be similar
to sibling or URD HCT.
PATIENTS AND METHODS
Data collection
The data on sibling and URD HCT were obtained solely from the Center for
International Blood and Marrow Transplant Research (CIBMTR), a voluntary
1Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN, USA; 2Service d’Hématologie et
Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France; 3Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France; 4CIBMTR (Center for International
Blood and Marrow Transplantation), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; 5Division of Biostatistics, Institute for Health and Society,
Medical College of Wisconsin, Milwaukee, WI, USA; 6University of Minnesota Medical Center Fairview, Minneapolis, MN, USA; 7European Group for Blood and Marrow
Transplantation, Leiden, The Netherlands; 8Sorbonne Universites, Centre de Recherche (CDR), Saint Antoine, Paris, France; 9Churchill Hospital, Oxford, UK; 10Department of
Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA; 11Centre Hospitalier Universitaire de LiFge, Domaine Universityaire du Sart
Tilman, Leige, Belgium; 12Division of Medical Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;
13Monacord, Centre Scientifique de Monaco, Monaco; 14The Bone Marrow Transplantation Department, Division of Internal Medicine, The Chaim Sheba Medical Center, Ramat-
Gan, Israel; 15Sheba Cord Blood Bank, Rama-Gan, Israel and 16Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical
Center, Minneapolis, MN, USA. Correspondence: Dr C Ustun, Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Mayo mail
code 480, 420 Delaware Street SE, Minneapolis, MN 55455, USA.
E-mail: custun@umn.edu
Received 8 September 2016; revised 11 December 2016; accepted 21 December 2016; accepted article preview online 25 January 2017; advance online publication, 14 February 2017
Leukemia (2017) 31, 1408–1414
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0887-6924/17
www.nature.com/leu
network of more than 450 transplant centers worldwide that report data
on consecutive HCTs. Patient, disease and HCT characteristics and outcome
data are reported on standardized forms submitted at the time of HCT
(baseline) and at 100 days, 6 months and annually thereafter. Data on UCB
HCT were obtained from the CIBMTR, Eurocord and the European Group
for Blood and Marrow Transplantation (EBMT). All patients provided
written informed consent for research. The Institutional Review Board of
the National Marrow Donor Program and Eurocord approved this study.
Inclusion criteria
Included are adult FLT3+ AML patients (aged ⩾ 18 years) who received
UCB HCT (single or double unit), sibling or URD HCT in CR1 or CR2 (second
CR) between 2007 and 2012 as data on FLT3 mutation status was
incompletely reported in prior years. The presence of FLT3+ mutation was
reported by the transplant center. Assay method and quantitative data are
not available. Previous HCT, ex vivo manipulated UCB, UCB combined with
another source of stem cells and haploidentical donor HCTs were
excluded. There were no exclusions regarding conditioning regimen,
alemtuzumab or antithymocyte globulin use or regimen intensity.
Definitions
Cytogenetic data (G-banding and/or fluorescence in situ hybridization
analyses) at diagnosis were classified according to the Southwest
Oncology Group/European Leukemia Net.33,34 LFS and CR were defined
according to the International Working Group criteria.35 Conditioning
regimen intensity was based on the report of Bacigalupo et al.36
End points
Relapse, the primary end point, was defined as morphological recurrence
of disease, and non-relapse mortality (NRM) was considered a competing
risk. Molecular (FLT3 mutation) evidence of leukemia as well as TK use
before or after HCT was not considered for relapse or measures of minimal
residual disease as these data were not available. Secondary end points
included LFS, NRM and overall survival (OS). Relapse or death from any
cause was considered an event for LFS—the opposite of treatment failure.
NRM was defined as death in remission, and disease relapse was
considered a competing risk. Neutrophil recovery was defined as achieving
an absolute neutrophil count of ⩾ 0.5 × 109/l for the first of three
measurements. Platelet recovery was defined as achieving platelets
⩾ 20× 109/l, unsupported by platelet transfusion for 7 days. Grade II–IV
acute and chronic graft-versus-host disease (GVHD) were graded using the
standard criteria.37,38 For neutrophil recovery, platelet recovery, acute and
chronic GVHD, death without specific event was considered a competing
risk. Study subjects were right-censored if corresponding event was not
observed at the end of study.
Statistical analysis
Patient-, disease- and transplant-related variables for donor types were
compared using χ2 statistics for categorical variables and the Kruskal–Wallis
test for continuous variables. Probabilities for relapse, NRM and GVHD were
calculated using the cumulative incidence estimator to accommodate
competing risks. Kaplan–Meier estimates were used to calculate the
probability of LFS and OS. The composite end point of GVHD-free (no
grade III/IV acute GVHD and no chronic GVHD), relapse-free survival point
estimates are provided using unadjusted Kaplan–Meier estimates. Time to
event end points were measured from the date of HCT. The Cox
proportional hazards regression model was used to identify risk factors
associated with acute and chronic GVHD, relapse, NRM, LFS (treatment
failure) and OS (overall mortality). As the primary variable of interest was
donor type (UCB vs HLA-matched sibling vs URD), this variable was
included in all steps of model building regardless of level of significance.
For other variables, a forward selection method was used to build the
regression models. Variables tested included age (18–29 vs 30–49 vs 50–69
years), gender (male vs female), performance score (90–100 vs o90), WBC
count at diagnosis (o10 vs 11–50× 109/l vs 450× 109/l), cytogenetic risk
group (favorable/intermediate vs adverse), time from diagnosis to CR1
(o5 vs 5–8 vs 48 weeks) and disease status at HCT (CR1 vs CR2). None of
the variables violated the assumptions of proportionality. Variables that
were statistically significant with P-value ⩽ 0.05 were retained in the final
models. There were no first-order interactions between the main effect
(donor type) and variables in the final multivariate models. Adjusted
probabilities of LFS and survival, and adjusted cumulative incidence
functions of NRM, relapse and acute and chronic GVHD were calculated
using the multivariate models, stratified on type of transplant and
weighted by the pooled sample proportion value for each prognostic
factor.39,40 These adjusted probabilities estimate likelihood of outcomes in
populations with similar prognostic factors. All analyses were carried out
using the statistical package SAS version 9.3 (Cary, NC, USA).
RESULTS
A total of 284 FLT3+ AML patients received HCT. Their clinical and
treatment characteristics are shown in Table 1. One hundred and
twenty-six patients received unrelated UCB (76 (60%) double units
UCB grafts), 91 patients received peripheral blood (n= 73) or bone
marrow (n= 18) from adult URD donors and 67 patients received
peripheral blood (n= 64) or bone marrow (n= 3) from HLA-
matched siblings. The median ages of the three graft-type groups
(UCB, sibling, URD) ranged from 41 to 48 years. Approximately
80% of HCTs occurred in CR1 and the most common conventional
cytogenetic risk was intermediate (i.e., normal karyotype) in all
treatment groups. The median time to achieve CR1 was 5 weeks
for the adult donor HCT and 6 weeks for UCB HCT. Among patients
transplanted in CR1, approximately half of sibling HCT recipients
received their HCT o12 weeks from achieving CR1 (median time
to HCT 11 weeks). In contrast, only 20% of UCB and URD recipients
received their HCT within 12 weeks from CR1 (median time to HCT
17 and 16 weeks, respectively). Most recipients of sibling and URD
HCT received myeloablative-conditioning regimen (MAC), while a
third of UCB recipients received a reduced intensity-conditioning
(RIC) regimen. Although most patients received calcineurin
inhibitor containing GVHD prophylaxis, mycophenolate was the
predominant second agent for UCB HCT vs methotrexate for
sibling and URD HCT. The median follow-up of survivors in each of
the treatment groups was 3 years.
Relapse and LFS
The primary outcome of interest was relapse after HCT. After
adjusting for the effects of WBC count at diagnosis and disease
status at the time of HCT, there were no significant differences in
relapse risks between UCB or HLA-matched siblings or URD
donors (Table 2), and no difference between UCB HCT compared
with URD (hazard ratio (HR) 1.05, 95% confidence interval (CI):
0.65–1.69, P= 0.84). The 3-year probabilities of relapse, adjusted
for WBC count and remission status were: HLA-matched sibling
44% (95% CI: 31–55); UCB 33% (95% CI: 25–42) and URD 33% (95%
CI: 24–42), P40.72 (Figure 1 and Supplementary Table 1). Pairwise
comparisons between each donor type were not significant (all
P40.16) (Supplementary Table 1). Relapse risks were higher in
patients with WBC 450 × 109/l at diagnosis compared with
⩽ 10 × 109/l (HR 2.72, 95% CI: 1.52–4.86, P= 0.0007) and in those
receiving HCT in CR2 compared with CR1 (HR 1.83, 95% CI: 1.17–
2.84, P= 0.008).
After adjusting for the effects of WBC count at diagnosis and
disease status at the time of HCT, the risk of treatment failure
(relapse or death; inverse of LFS) was similar after UCB and URD
HCTs as compared with HLA-matched sibling HCT (Table 2).
Similarly, there was no significant difference in the risk of
treatment failure after UCB compared with URD HCT (HR 1.27,
95% CI: 0.87–1.85, P= 0.21). The 3-year probabilities of LFS, after
adjusting for WBC count and disease status were 43% (95% CI: 30–
54), 39% (95% CI: 30–47) and 50% (95% CI: 40–60) after HLA-
matched sibling, UCB and URD HCTs, respectively, P= 0.42
(Figure 2 and Supplementary Table 1). The risk of treatment
failure was greater in patients with WBC450 × 109/l at diagnosis
(HR 2.16, 95% CI: 1.37–3.40, P= 0.0009) and for patients receiving
HCTs in CR2 (HR 1.67, 95% CI: 1.17–2.39, P= 0.005).
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Table 1. Patients characteristics
Variable HLA-matched sibling Unrelated donor Umbilical cord blood P-value
Number 67 91 126
Gender 0.91
Male 31 (46) 39 (43) 55 (44)
Female 36 (54) 52 (57) 71 (56)
Age (years) 0.02
Median (range) 48 (18–59) 43 (19–60) 41 (18–67) 0.002
18–29 5 (7) 21 (23) 34 (27)
30–49 31 (46) 39 (43) 58 (46)
50–69 31 (36) 31 (34) 34 (27)
Performance score 0.04
o90 21 (31) 28 (31) 22 (17)
90–100 42 (63) 60 (66) 101 (80)
Not reported 4 (6) 3 (3) 3 (2)
WBC count at diagnosis o0.001
⩽ 10x109/l 18 (27) 21 (23) 22 (17)
11–50x109/l 26 (39) 31 (34) 29 (23)
450x109/l 22 (33) 34 (37) 41 (33)
Not reported 1 (1) 5 (5) 34 (27)
Cytogenetic risk 0.65
Favorable 2 (3) 3 (3) 5 (4)
Intermediate 55 (82) 73 (80) 106 (84)
Poor 9 (13) 11 (12) 8 (6)
Missing 1 (1) 4 (4) 7 (6)
Recipient CMV 0.30
Negative 25 (37) 35 (38) 39 (31)
Positive 42 (63) 54 (59) 84 (67)
Missing 0 2 (2) 3 (2)
Time to CR1 (weeks) 0.02
⩽ 5 36 (54) 44 (48) 37 (29)
6–8 18 (27) 24 (26) 39 (31)
48 8 (12) 16 (18) 36 (29)
Not reported 5 (7) 7 (8) 14 (11)
Disease status, HCT 0.82
CR1 52 (78) 73 (80) 97 (77)
CR2 15 (22) 18 (20) 29 (23)
Duration of CR1 0.21
o12 months 12 (80) 11 (61) 17 (59)
⩾ 12 months 2 (13) 5 (28) 3 (10)
Missing 1 (7) 2 (11) 9 (31)
Conditioning regimen
Myeloablative
TBI+Cy±other 37 (55) 35 (38) 45 (36)
TBI+other 2 (3) 0 5 (4)
Bu+Cy/other 22 (33) 42 (46) 33 (26)
Othera 0 0 3 (2)
Reduced intensity
Bu+Flu 4 (6) 8 (9) 0
TBI 200 cGy± Flu±other 0 3 (3) 40 (32)
Othera 2 (3) 3 (3) 0
Graft type
Bone marrow 3 (4) 18 (20)





CsA/Tac+MMF 10 (15) 17 (19) 97 (77)
CsA/Tac+MTX 42 (63) 69 (76) 1 (o1)
CsA/Tac+other 15 (22) 2 (2) 21 (17)
Otherb 0 3 (3) 7 (6)
Transplant period 0.68
2007–2009 33 (49) 47 (52) 57 (45)
2010–2012 34 (51) 44 (48) 69 (55)
Follow-up, median (range), months 37 (13–61) 37 (12–65) 37 (6–84)
Abbreviations: ATG, antithymocyte globulin; Bu, busulfan; Clo, clofarabine; CMV, cytomegalovirus; CR, complete remission; CsA, cyclosporine; Cy,
cyclophosphamide; Flu, fludarabine; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplant; Mel, melphalan; MMF, mycophenolate mofetil; MTX,
methotrexate; RIC, reduced intensity conditioning; Tac, tacrolimus; TBI, total body irradiation; Thio, thiotepa; TLI, total lymphoid irradiation; WBC, white
blood cell. aMAC other: Flu+Mel+Thio+ATG, n= 3 and RIC other: Bu+Clo, n= 1; Flu+Mel, n= 1; TLI+ATG, n= 3. bOther GVHD prophylaxis: MTX, n= 2; unknown,
n= 9.
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NRM and OS
Compared with HLA-matched sibling HCT, NRM risks were higher
after UCB HCT, but not after URD HCT (Table 2). NRM risks were
marginally, but not significantly, higher after UCB HCT compared
with URD HCT (HR 1.72, 95% CI: 0.95–3.12, P= 0.07). The 3-year
probabilities of NRM were 14% (95% CI: 7–23), 28% (95% CI: 20–
36) and 17% (95% CI: 10–25) after HLA-matched sibling, UCB and
URD HCTs, respectively (Figure 3 and Supplementary Table 1).
However, there were no significant differences in risks of overall
mortality between the three donor types (Table 2). The 3-year
probabilities of OS, adjusted for disease status were 46% (95% CI:
33–59), 43% (95% CI: 34–52) and 50% (95% CI: 39–60) after
HLA- matched sibling, UCB and URD HCTs, respectively (P= 0.26
(Figure 4). The most common cause of death was disease relapse
for each treatment group (Supplementary Table 2). Overall
mortality was higher for HCTs in CR2 (1.55, 95% CI: 1.08–2.22,
P= 0.02) (Table 2).
Hematopoietic recovery and GVHD
The median time to reach neutrophil engraftment was longer for
UCB HCT (day +22) compared with HLA-matched sibling and URD
HCTs (day +14 for each) (Po0.001). However, by day +60, there
was no significant difference in engraftment among the three
groups. Compared with HLA-matched sibling HCT, grade II–IV
acute GVHD risks were higher after URD HCT (HR 1.85, 95% CI:
Table 2. Multivariate analysis using proportional hazards model for relapse, NRM, LFS and OS
Variables Relapse NRM LFS OS
N RR 95% CI P-value RR 95% CI P-value RR 95% CI P-value RR 95% CI P-value
Graft source/donor 0.72 0.01 0.42 0.26
BM/PB sibling 67 1 1 1 1
BM/PB unrelated 91 0.81 0.49–1.36 0.43 1.49 0.65–3.38 0.34 0.94 0.61–1.45 0.78 1.09 0.69–1.70 0.72
UCB 126 0.86 0.52–1.42 0.54 2.83 1.33–6.04 0.007 1.19 0.79–1.80 0.40 1.36 0.9–2.06 0.14
Time from diagnosis to CR1 0.056
o5 weeks 117 1
5–8 weeks 81 0.37 0.18–0.75 0.0063
⩾ 8 weeks 60 0.74 0.38–1.41 0.36
Missing 26 0.66 0.25–1.70 0.38
WBC count at diagnosis 0.001 0.0031
⩽ 10 61 1 1
10–50 86 1.48 0.78–2.79 0.23 1.44 0.89–2.33 0.14
450 97 2.72 1.52–4.86 0.0007 2.16 1.37–3.40 0.0009
Missing 40 1.18 0.52–2.66 0.69 1.22 0.67–2.21 0.52
Disease status before HCT
CR1 222 1 1 1
CR2 62 1.83 1.17–2.84 0.0076 1.67 1.17–2.39 0.0052 1.55 1.08–2.22 0.019
Abbreviations: BM, bone marrow; CI, confidence interval; CR, complete remission; HCT, hematopoietic cell transplantation; LFS, leukemia-free survival; NRM,
non-relapse mortality; OS, overall survival; PB, peripheral blood; RR, relative risk; UCB, umbilical cord blood; WBC, white blood cell.
Figure 1. Adjusted cumulative incidence of relapse by donor type.
The 3-year probabilities of relapse, adjusted for WBC count and
remission status, were 44% (95% CI: 31–55), 33% (95% CI: 25–42) and
33% (95% CI: 24–42) after HLA-matched sibling, UCB and URD HCTs,
respectively (P= 0.72).
Figure 2. Adjusted LFS by donor type. The 3-year probabilities of
LFS, after adjusting for WBC and disease status were 43% (95% CI:
30–54), 39% (95% CI: 30–47) and 50% (95% CI: 40–60) after HLA-
matched sibling, UCB and URD HCTs, respectively (P= 0.42).
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1.08–3.15, P= 0.02), but were not statistically different after UCB
HCT (HR 1.66, 95% CI: 0.99–2.78, P= 0.06). The day-100 prob-
abilities of acute GVHD were 27% (95% CI: 17–38), 42% (95% CI:
33–50) and 45% (95% CI: 35–56) after HLA-matched sibling, UCB
and URD HCTs, respectively. In contrast, chronic GVHD risks were
significantly lower after UCB HCT compared with HLA-matched
sibling (HR 0.59, 95% CI: 0.37–0.94, P= 0.03) or URD HCT (HR 0.50,
95% CI: 0.32–0.76, P= 0.001). Chronic GVHD risks were similar after
HLA-matched sibling or URD HCT (HR 1.19, 95% CI: 0.77–1.83,
P= 0.44). The 3-year probabilities of chronic GVHD were 62% (95%
CI: 49–75), 32% (95% CI: 24–41) and 60% (95% CI: 49–70) after
HLA-matched sibling, UCB and URD HCTs, respectively.
GVHD-free, relapse-free survival at year 1 and 3 years
was slightly, but not significantly, higher in UCB HCT (26%,
95% CI: 18–34 and 20%, 95% CI: 14–28) vs sibling HCT
(16%, 95% CI: 9–26 and 5%, 95% CI: 1–12) or URD HCT
(16%, 95% CI: 10–25 and 8%, 95% CI: 3–15), P= 0.12.
Prognostic factors in UCB HCT
In the cohort of UCB HCTs, the 2-year relapse risk was significantly
lower in patients receiving MAC compared with RIC (25%, 95% CI:
16–35% vs 45%, 95% CI: 30–61, P= 0.03). In contrast, NRM risk at 2
years was significantly higher in patients receiving MAC compared
with RIC (37%, 95% CI: 16–35% vs 13%, 95% CI: 4–25, P= 0.009).
This resulted in similar 2-year LFS for MAC (38%, 95% CI: 27–49)
and RIC (42%, 95% CI: 27–58, P= 0.65) UCB HCTs and similar 2-year
OS for MAC (40%, 95% CI: 30–51) and RIC (52%, 95% CI: 37–67,
P= 0.21). The number of UCB units infused (i.e., single vs double)
had no impact on any reported outcomes.
DISCUSSION
In this study, we found that FLT3+ AML patients receiving UCB
HCT had no statistically significant difference in relapse and LFS
rates compared with HLA-matched sibling or URD HCTs. This is
concordant with prior studies comparing UCB with other graft
sources.24,30,41 In our study, despite a greater proportion of UCB
recipients receiving RIC than MAC (32% vs sibling 9% and MUD
15%), which is associated with higher relapse rates in patients with
AML, with or without FLT3 mutation,19,42 the adjusted risks of
relapse and treatment failure were similar for the three groups.
UCB HCT patients also had a longer duration to reach CR1.
Therefore, our data support an inference that there is graft-versus-
leukemia effect after single or double UCB HCT,24,43 even for FLT3+
AML and its attendant high risk of relapse. Consistent with our
large multicenter study, a single center study on 66 AML patients
(22 FLT3+ and 44 FLT3− ) receiving UCB HCT showed that the
negative effect of FLT3+ AML was overcome by UCB HCT.32 Two-
year relapse rate was for FLT3+ AML 29%, whereas 36% for FLT−
AML, which led to LFS: 48% vs 37%, and OS: 47% vs 42% in FLT3+
AML vs FLT3− AML, respectively). As the high-risk nature of FLT3+
AML and the need for aggressive consolidation with allogeneic
HCT is well recognized, our observation has major clinical
implications for FLT3+ AML patients in CR after initial therapy.
Non-HCT consolidative chemotherapies may lead to increased
FLT3 ligand plasma levels and thus resistance to further
therapies.44 Our data demonstrates that performing allogeneic
HCT as consolidation in CR1 yields favorable outcomes given
poorer survival for HCT during CR2.
The higher NRM after UCB HCT may be attributed to slower
hematopoietic recovery and subsequent infections.24,45,46 Some
UCB reports suggest that acute GVHD risks are similar or lower
than after HLA-matched sibling HCT or URD HCT.24,47,48 The
notably lower risks of chronic GVHD offset these early complica-
tions in UCB HCT.24,49–51 In this study, while the incidence of acute
GVHD after UCB was not significantly different than other graft
types; however, chronic GVHD was significantly less frequent after
UCB HCT. Although there was no statistically significant difference
observed, OS was slightly lower and GRFS was slightly better for
UCB HCT compared with other donor grafts.
We had insufficient data available to separately analyze FLT3/ITD+
or FLT3/TKD+ AML or the FLT3-mutant allelic burden5,9,52,53 and
had only incomplete data on NPM1 mutations. In the literature,
FLT3/ITD mutation is frequently associated with poor prognosis;
this is less certain for the FLT3/TKD mutation.4,15 While the
coexistence of NPM1 mutations in patients with FL3/ITD+ AML
may influence the risk of relapse,21,54 a recent study from MD
Anderson showed that allogeneic HCT remained statistically
significant with improved RFS and OS independent of FLT3/ITD
allelic ratio and NPM1 mutation status in multivariate regression
models.55 This might not be true for RIC allogenic HCT.56 In
our study, we were unable address this controversial issue.
Interestingly, we observed that high WBC (450 × 109/l) at
Figure 3. Adjusted cumulative incidence of NRM by graft source.
The 3-year probabilities of NRM, after adjusting for time from
diagnosis to CR1 were 14% (95% CI: 7–23), 28% (95% CI: 20–36) and
17% (95% CI: 10–25) after HLA-matched sibling, UCB and URD HCTs,
respectively. Pairwise comparisons: UCB vs URD, P= 0.07; UCB vs
sibling, P= 0.02; URD vs sibling, P= 0.47.
Figure 4. Adjusted OS by donor type. The 3-year probabilities of OS,
adjusted for disease status were 46% (95% CI: 33–59), 43% (95% CI:
34–52) and 50% (95% CI: 39–60) after HLA-matched sibling, UCB and
URD HCTs, respectively (P= 0.26).
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diagnosis was found to be associated with a higher relapse risk57
and it may be correlated with the FLT3/ITD allelic ratio.1,5,57,58 As
expected, HCT during CR2 was also associated with significant
increased relapse and with inferior LFS and OS. Another potential
limitation of the study is that the available data from the three
international registries had differing number of cases using each
graft type. While referral patterns and graft choices and the
resultant influence on outcomes might differ in the cases reported
from each registry, we could not directly probe this possibility with
available data. We could not evaluate HCT-comorbidity index,
shown to be associated with NRM and OS,59 because of
insufficient data.
These data support the use of UCB as a donor graft for patients
with FLT3+ AML who lack a readily available HLA-matched sibling
donor. Our data also suggest that delay to HCT in these patients
with an expectedly short CR1 adversely affects outcomes, possibly
further favoring the more quickly available UCB. Studies on the
use of partially matched related donors, as yet another rapidly
available donor type are warranted. Additionally, following any
donor HCT, post-transplant maintenance with FLT3 inhibitors
seems promising because 30–40% of patients still relapse after
allogeneic HCT regardless of graft type.60
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